Acquisition - August 5, 2014
Roche to buy Santaris Pharma
Swiss Roche has announced that the company has agreed to acquire Danish biopharmaceutical firm Santaris Pharma for USD 450 million. The plan is to expand discovery and development of RNA-targeting medicines. Santaris Pharma has pioneered its proprietary Locked Nucleic Acid (LNA) platform that has contributed to an emerging era of RNA-targeting therapeutics, according to Roche which […]
Agreement - January 13, 2014
Santaris Pharma announce agreement with GSK to develop RNA-targeted medicines
Santaris Pharma A/S have announced that they have signed an agreement with GlaxoSmithKline (GSK), whereby, pursuant to an option right, GSK gains access to Santaris’ Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines. Under the terms of the agreement, GSK can obtain rights to utilize Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug Platform […]
Drug Development Pharma - September 4, 2013
Shire extends partnership with Santaris Pharma
The two companies extend their existing partnership in rare genetic disease space. The Danish clinical stage biopharmaceutical company Santaris Pharma focuses on the discovery and development of RNA-targeted therapies. Under the terms of agreement, Shire will have the right to nominate additional collaboration targets for drug discovery and development and Santaris will receive an upfront […]
